PDGFR

Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference

Retrieved on: 
Martedì, Maggio 14, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Cardiology, GOSS, Biomarker, Pulmonary hypertension, PAH, Treatment, Orthostatic hypertension, Conference, CSF1R, PDGFR, Fibrosis, Poster, Hemodynamics, Pharmaceutical industry

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), will present updated seralutinib TORREY open-label extension data at the American Thoracic Society 2024 International Conference, which takes place May 17-22 in San Diego, California.

Key Points: 
  • Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), will present updated seralutinib TORREY open-label extension data at the American Thoracic Society 2024 International Conference, which takes place May 17-22 in San Diego, California.
  • Details for the oral presentation related to seralutinib, an inhaled, PDGFR, CSF1R and c-KIT inhibitor, designed for the treatment of pulmonary hypertension, are as follows:
    Gossamer also will present additional data on seralutinib via poster.
  • Details for those posters are as follows:
    Poster Title: TORREY Phase 2 Study of Seralutinib in Pulmonary Arterial Hypertension (PAH): Circulating Biomarkers of Proliferation, Inflammation, and Fibrosis Improve with Treatment
    Poster Session: D109 Now We Got Bad Blood: RSF/PC Joint Session on Pulmonary Vascular Disease
    Poster Title: Cardiac Effort Is Less Variable Than Six-minute Walk Distance, Correlates with Hemodynamics and Is Consistent with REVEAL 2.0 Risk Score in a Sub-study of the TORREY Phase 2 PAH Trial

Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Venerdì, Aprile 5, 2024
Technology, Research, Nanotechnology, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, Clinical trial, PDT, Macrophage, Downregulation and upregulation, Ovarian cancer, BRCA, ECM, Pericyte, Apoptosis, Nanoparticle, Cervical cancer, GBM, Patient, Neoplasm, Doxorubicin, Traffic barrier, Cancer, Triple-negative breast cancer, Proteomics, AACR, Glioblastoma, Pancreatic cancer, Phenotype, PARP, Cisplatin, Immunogenic cell death, Large intestine, TNBC, Animal, PDGFR, Pharmaceutical industry

Novocure (NASDAQ: NVCR) today announced 20 presentations on Tumor Treating Fields (TTFields) therapy will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2024, to be held April 5 to 10 in San Diego.

Key Points: 
  • Novocure (NASDAQ: NVCR) today announced 20 presentations on Tumor Treating Fields (TTFields) therapy will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2024, to be held April 5 to 10 in San Diego.
  • Presentations from Novocure-sponsored and partner programs include:
    Tumor Treating Fields (TTFields) targeted self assembling nanoparticles for pancreatic cancer treatment: In vitro and in vivo assessment.
  • Tumor Treating Fields (TTFields) induce an anti-tumor immune response in a pancreatic cancer mouse model.
  • Tumor Treating Fields (TTFields) show efficacy in Triple-Negative breast cancer (TNBC) cells alone and in combination with PARP inhibitor Talazoparib.

Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro

Retrieved on: 
Lunedì, Dicembre 4, 2023
Food, Syndrome, Chronic myelogenous leukemia, Acute lymphoblastic leukemia, Tmax, FDA, Plasma, Imatinib, Blood, NDA, Therapy, PDGFR, Parkinson's disease, Pancreatic serous cystadenoma, Patient, Mastocytosis

BOSTON and ATLANTA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced the U.S. Food and Drug Administration has granted a pre-New Drug Application (pre-NDA) meeting to be held in January 2024 to discuss the requirements for approval of IkT-001Pro and to review the data establishing doses of IkT-001Pro bioequivalent to 400 mg and 600 mg imatinib mesylate. The Company expects to provide an update following the meeting.

Key Points: 
  • The Company expects to provide an update following the meeting.
  • “We are pleased that the FDA has granted a pre-NDA meeting to discuss the parameters for approval of IkT-001Pro,” stated Dr. Milton Werner, President and Chief Executive Officer of Inhibikase Therapeutics.
  • Across all doses, there were only mild adverse events observed, including just two adverse events for IkT-001Pro at the highest dose comparison.
  • Pharmacokinetic profiles for imatinib delivered by IkT-001Pro and imatinib mesylate were similar at equivalent doses.

87.5% ORR | Abbisko presented two clinical updates of Pimicotinib at the 2023 CTOS Annual Meeting

Retrieved on: 
Martedì, Novembre 7, 2023
PD, US, BTD, TGCT, Priority, Human, European Medicines Agency, IDMC, Male, Liver injury, Hip, BIRC, Ankle, PRO, Pain, IRC, Completeness, Part Two, Response evaluation criteria in solid tumors, QD, 1.1, MRI, Itch, AST, US FDA, CSF1, Motion, Rash, Neoplasm, Independent Review Committee, PK, ORR, Part, Safety, Therapy, ALT, Patient, LDH, ASCO, PDGFR, Contraindication, Nilotinib, III, DOR, Imatinib, Breakthrough therapy, Clinical trial, Hepatotoxicity, Knee, FDA, Dyslipidemia, CPK, RES, SD, RECIST, Pharmaceutical industry, Nursing

SHANGHAI, Nov. 6, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) announced that two major clinical updates of its CSF-1R inhibitor pimicotinib（ABSK021）were presented at the 2023 Connective Tissue Oncology Society Annual Meeting, which is held in Ireland from November 1 to 4, 2023.

Key Points: 
  • SHANGHAI, Nov. 6, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) announced that two major clinical updates of its CSF-1R inhibitor pimicotinib（ABSK021）were presented at the 2023 Connective Tissue Oncology Society Annual Meeting, which is held in Ireland from November 1 to 4, 2023.
  • The two clinical updates include reporting the design of the pivotal global multi-center phase III clinical trial and the further update of the phase Ib clinical trial of pimicotinib.
  • In 2023, the U.S. FDA conferred Breakthrough Therapy Designation and the European Medicines Agency granted Priority Medicine Designation upon Pimicotinib treatment of TGCT.
  • Here, we report the phase 1b safety and efficacy results of Pimicotinib in TGCT patients over a 1-year follow-up.

Elevar Therapeutics Presents AACR 2023 Poster Demonstrating Rivoceranib as Most Selective VEGFR-2 Inhibitor When Compared to Other TKIs With Known Activity Against VEGFR-2

Retrieved on: 
Martedì, Aprile 18, 2023
TKI, ACC, AACR, PDGFR, Hepatocellular carcinoma, Progression-free survival, ESMO, American Society of Clinical Oncology, Food and Drug Administration, NDA, Cancer, American Association for Cancer Research, Toxicity, Adenoid cystic carcinoma, Oncology, FLT4, European Society for Medical Oncology, Liver cancer, ASCO, Congress, Patient, Sorafenib, VEGFR, Toxic encephalopathy, Neoplasm, Apatinib, PD-1, FDA, Therapy, FLT1, Society, HCC, Food, Pharmaceutical industry, Lyn

The results of the analysis were shared today in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando.

Key Points: 
  • The results of the analysis were shared today in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando.
  • For the biochemical analysis, the activity of rivoceranib and 10 U.S. Food and Drug Administration (FDA)-approved TKIs with known activity against VEGFR-2 were compared against a panel of 270 kinases.
  • Substantial differences in overall residual kinase activity were observed across the panel of 270 kinases among the 11 inhibitors.
  • Rivoceranib is the most selective inhibitor of VEGFR-2 kinase activity among the tested inhibitors.

AB Science today announced publication of results from its positive study of masitinib in severe asthma uncontrolled by oral corticosteroids in the peer-reviewed Journal of Asthma and Allergy

Retrieved on: 
Martedì, Giugno 7, 2022
Science, Tyrosine kinase inhibitor, OCS, The New England Journal of Medicine, Time, Company, Holgate, Research, Cell, Euronext Paris, Marketing, Allosteric regulation, Survival, Veni, vidi, vici, Inflammation, Suzanne Comhaire-Sylvain, Treatment, University of Oradea, Failure, Maintenance, ERS, University, Clinical & Experimental Allergy, Patient, PKI Resource Query Protocol, Risk, Randomized controlled trial, AMF, Safety, Lists of diseases, Phenotype, AB, MD, B cell, Population, Degenerative disease, Epigenetics of diabetes Type 2, Medicine, PDGFR, Aix-Marseille University, Veterinary medicine, Journal of Asthma and Allergy, Mast cell, Brad Komminsk, Publishing, Pharmaceutical industry, Vaccine, Airline, Masitinib, Asthma

Results from this phase 3 study showed that corticosteroid-dependent severe asthma patients treated with masitinib at 6.0 mg/kg/d had a lower risk of severe asthma exacerbations compared with those in a placebo-control group that did not receive masitinib.

Key Points: 
  • Results from this phase 3 study showed that corticosteroid-dependent severe asthma patients treated with masitinib at 6.0 mg/kg/d had a lower risk of severe asthma exacerbations compared with those in a placebo-control group that did not receive masitinib.
  • Phase 3 study (AB07105) evaluating oral masitinib at 6 mg/kg/d versus placebo in severe asthma uncontrolled by oral corticosteroids (OCS) met its primary endpoint.
  • Masitinib significantly decreased the rate of severe asthma exacerbations in patients with severe asthma uncontrolled by OCS.
  • 13 months)
    Masitinib has a unique positioning in severe asthma, in terms of administration (oral administration), mechanism of action, targeted population, and broader eosinophil level.

Cogent Biosciences Reports Recent Business Highlights and First Quarter 2022 Financial Results

Retrieved on: 
Martedì, Maggio 10, 2022
D, Forward-looking statement, Mutation, Private Securities Litigation Reform Act, EHA, IND, Nasdaq, Twitter, GLOBE, European Hematology Association, APEX, Pleural effusion, Safety, Research, Patient, Stromal cell, B cell, American Association, Risk, Mastocytosis, Annual report, American Association for Cancer Research, GIST, LinkedIn, PDGFR, Investigational New Drug, Congress, Cash, SEC, AACR, CEO, HER2/neu, Toxic epidermal necrolysis, Growth, FLT3, KIT, Edema, Social media, FGFR2, Pharmaceutical industry, PEAK, CSF1R, Cogent

CAMBRIDGE, Mass. and BOULDER, Colo., May 10, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced financial results for the first quarter ended March 31, 2022.

Key Points: 
  • and BOULDER, Colo., May 10, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.(Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced financial results for the first quarter endedMarch 31, 2022.
  • We continue to make significant progress towards our strategic priorities for 2022, said Andrew Robbins, President and CEO of Cogent Biosciences.
  • R&D Expenses: Research and development expenses were $25.5 million for the first quarter of 2022 compared to $8.2 million for the first quarter of 2021.
  • G&A Expenses:General and administrative expenses were $5.9 million for the first quarter of 2022 compared to $4.6 million for the first quarter of 2021.

Telix Pharmaceuticals Announces Licence Agreement with Lilly for Olaratumab

Retrieved on: 
Domenica, Aprile 10, 2022
Cancer, LinkedIn, TGA, American Cancer Society, Human, Degenerative disease, Partnership, Metastasis, Diagnosis, Marketing, Forward-looking statement, Sarcoma, Multimedia, Olaratumab, Overalls, STS, Survival, Research, Program, Prognosis, Incidence, Achievement, Death, Doxorubicin, Food, TLX, ASX, Australian Securities Exchange, Industry, Safety, MTR, Eli Lilly and Company, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PDGFR, FDA, Acquisition, Patient, Gallium, Pharmaceutical industry, Vaccine, Animal, Company, Telix, EU, Lilly

MELBOURNE, Australia and INDIANAPOLIS, April 10, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, "Telix", the "Company") today announces that it has entered into a licence agreement with Eli Lilly and Company ("Lilly") under which Telix is granted exclusive worldwide rights to develop and commercialise radiolabelled forms of Lilly's olaratumab antibody for the diagnosis and treatment of human cancers.

Key Points: 
  • MELBOURNE, Australia and INDIANAPOLIS, April 10, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, "Telix", the "Company") today announces that it has entered into a licence agreement with Eli Lilly and Company ("Lilly") under which Telix is granted exclusive worldwide rights to develop and commercialise radiolabelled forms of Lilly's olaratumab antibody for the diagnosis and treatment of human cancers.
  • The exclusive worldwide licence will allow Telix to repurpose olaratumab as a targeting agent for radiopharmaceutical imaging and therapy of cancer.
  • The agreement also includes an option for Lilly to be granted an exclusive licence to a radiolabelled companion diagnostic which would be developed by Telix.
  • Telix retains termination rights typical to licence agreements of this nature to enable the Company to exit the agreement based on a development or commercial basis.

China Anlotinib Hydrochloride Market Research Report 2021: A Novel Small Molecule Multi-target Tyrosine Kinase Inhibitor that Effectively Inhibits Kinases Like VEGFR, PDGFR, FGFR, and c-Kit - ResearchAndMarkets.com

Retrieved on: 
Martedì, Dicembre 7, 2021
Health, Pharmaceutical, MTC, VEGFR, Thyroid cancer, NMPA, Sarcoma, Lung cancer, FGFR, The Different Company, Medullary thyroid cancer, PDGFR, Cancer, Stomach, Colorectal cancer, Patient, Large-cell lung carcinoma, China Energy Research Report, CAGR, Dosage form, Squamous cell carcinoma, Incidence, Pollution, Marketing, NSCLC, Research report, Animal, Pharmaceutical industry, Generic drug, Medical imaging, Iron

The "Research Report on China's Anlotinib Hydrochloride Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Research Report on China's Anlotinib Hydrochloride Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • Anlotinib hydrochloride is a novel small molecule multi-target tyrosine kinase inhibitor that effectively inhibits kinases like VEGFR, PDGFR, FGFR, and c-Kit with anti-tumor angiogenesis and tumor growth inhibition effects.
  • Anlotinib hydrochloride was approved for marketing under the trade name FuKeWei by the NMPA on May 9, 2018, for the third-line treatment of patients with advanced non-small cell lung cancer (NSCLC).
  • The fast time to market anlotinib hydrochloride was made possible by the Chinese government's support for accelerated evaluation and approval of innovative drugs.

Ayvakit Patent, Sales & Clinical Trials Market Insight Report 2021-2028 - ResearchAndMarkets.com

Retrieved on: 
Mercoledì, Novembre 3, 2021
Health, Pharmaceutical, Science, Breast cancer, Cancer, Melanoma, Mutation, Research, Drug development, Colorectal cancer, Data, Patient, US FDA, Adoption, KIT, Government, European Commission, PDGFR, Patent, Growth, Exon, Lung cancer, Therapy, PDGFRA, GIST, Clinical trial, Pharmaceutical industry

The "Ayvakit Patent, Sales & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Ayvakit Patent, Sales & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering.
  • Keeping in mind the sales in previous years and ongoing clinical trials, the report analyzes that the global sales will reach US$ 1 Billion by 2028.
  • The rapid approval of drugs from this class will have a negative impact on the growth of Ayvakit market.
  • Ayvakit Patent, Sales & Clinical Trials Insight 2028 Report Analysis & Data Highlights: